Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of an Adeno-associated Virus Vector (AAV2/5-OPTIRPE65) for Gene Therapy of Adults and Children With Retinal Dystrophy Owing to Defects in RPE65 (LCA2)
Phase of Trial: Phase I/II
Latest Information Update: 20 Dec 2017
At a glance
- Drugs A001-MeiraGTx (Primary)
- Indications Retinal dystrophies
- Focus Adverse reactions
- Sponsors MeiraGTx
- 16 Aug 2017 Planned End Date changed from 1 Dec 2023 to 1 Apr 2023.
- 16 Aug 2017 Planned primary completion date changed from 1 Nov 2023 to 1 Apr 2023.
- 07 Dec 2016 Status changed from not yet recruiting to recruiting.